Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

ABSTRACT:

Objectives/hypothesis

Assess tumor suppressor p53 (TP53) functional mutations in the context of other biomarkers in advanced larynx cancer.

Study design

Prospective analysis of pretreatment tumor TP53, human papillomavirus (HPV), Bcl-xL, and cyclin D1 status in stage III and IV larynx cancer patients in a clinical trial.

Methods

TP53 exons 4 through 9 from 58 tumors were sequenced. Mutations were grouped using three classifications based on their expected function. Each functional group was analyzed for response to induction chemotherapy, time to surgery, survival, HPV status, p16INK4a, Bcl-xl, and cyclin D1 expression.

Results

TP53 mutations were found in 22 of 58 (37.9%) patients with advanced larynx cancer, including missense mutations in 13 of 58 (22.4%) pa

SUBMITTER: Scheel A 

PROVIDER: S-EPMC5002993 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature